title: Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy.
authors.forename: Elio
authors.initials: E
authors.lastname: Castagnola
authors.forename: Sandro
authors.initials: S
authors.lastname: Dallorso
authors.forename: Maura
authors.initials: M
authors.lastname: Faraci
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Morreale
authors.forename: Daniela
authors.initials: D
authors.lastname: Di Martino
authors.forename: Emilio
authors.initials: E
authors.lastname: Cristina
authors.forename: Lucia
authors.initials: L
authors.lastname: Scarso
authors.forename: Edoardo
authors.initials: E
authors.lastname: Lanino
mesh_terms: D000361:Agammaglobulinemia / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D020031:Epstein-Barr Virus Infections / Q000628:therapy; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000821:virology*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab